8-K Announcements
6Material company update
Mar 18, 2026·SEC
Material company update
Mar 9, 2026·SEC
Material company update
Feb 11, 2026·SEC
Protalix BioTherapeutics, Inc.(PLX)Earnings, Financials & Key Ratios
PLX•AMEX
$2.02
$162M mkt cap·Price updated May 6, 2026
AboutProtalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.Show more
- Revenue$53M-1.2%
- EBITDA-$4M-177.3%
- Net Income-$7M-325.2%
- EPS (Diluted)-0.08-329.8%
- Gross Margin48.82%-10.3%
- EBITDA Margin-7.65%-178.2%
- Operating Margin-10.43%-242.2%
- Net Margin-12.52%-328.0%
- ROE-14.44%-289.1%
- ROIC-11.64%-232.0%
- Debt/Equity0.17+34.9%
- Interest Coverage-4.62-225.2%
PLX Key Insights
Protalix BioTherapeutics, Inc. (PLX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 21.9%
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 3.1% through buybacks
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PLX Price & Volume
Protalix BioTherapeutics, Inc. (PLX) stock price & volume — 10-year historical chart
Loading chart...
PLX Growth Metrics
Protalix BioTherapeutics, Inc. (PLX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years28.3%
5 Years-3.46%
3 Years3.45%
TTM-1.23%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-325.24%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-387.03%
Return on Capital
10 Years-51.46%
5 Years-39.04%
3 Years10.67%
Last Year-10.62%
PLX Recent Earnings
Protalix BioTherapeutics, Inc. (PLX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (27%)●Beat Revenue 6/12 qtrs (55%)
Q2 2026Latest
Mar 18, 2026EPS
$0.07
Est $0.01
-800.0%
Revenue
$9M
Est $18M
-50.1%
Q4 2025
Nov 13, 2025EPS
$0.03
Est $0.06
-50.0%
Revenue
$18M
Est $14M
+25.3%
Q3 2025
Aug 14, 2025EPS
$0.00
Est $0.03
-93.3%
Revenue
$16M
Est $13M
+16.1%
Q2 2025
May 9, 2025EPS
$0.05
Est $0.08
-162.5%
Revenue
$10M
Est $23M
-56.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 18, 2026 | $0.07vs $0.01-800.0% | $9Mvs $18M-50.1% |
| Q4 2025 | Nov 13, 2025 | $0.03vs $0.06-50.0% | $18Mvs $14M+25.3% |
| Q3 2025 | Aug 14, 2025 | $0.00vs $0.03-93.3% | $16Mvs $13M+16.1% |
| Q2 2025 | May 9, 2025 | $0.05vs $0.08-162.5% | $10Mvs $23M-56.2% |
Based on last 12 quarters of dataView full earnings history →
PLX Peer Comparison
Protalix BioTherapeutics, Inc. (PLX) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 SRPT | 2.42B | 23.03 | -3.23 | 15.58% | 2.98% | 4.89% | 0.91 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 KRYS | 8.52B | 288.90 | 42.24 | 33.94% | 53.92% | 19.25% | 0.01 | |
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% | |||
 BMRN | 10.5B | 54.60 | 30.33 | 12.87% | 8.29% | 4.41% | 0.11 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% |
Compare PLX vs Peers
Protalix BioTherapeutics, Inc. (PLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PLX Income Statement
Protalix BioTherapeutics, Inc. (PLX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 21.08M | 34.24M | 54.69M | 62.9M | 38.35M | 47.64M | 65.49M | 53.4M | 52.74M |
| Revenue Growth % | 129.13% | 62.44% | 59.73% | 15% | -39.03% | 24.22% | 37.48% | -18.47% | -1.23% |
| Cost of Goods Sold | 15.23M | 9.3M | 10.89M | 10.87M | 16.35M | 19.59M | 22.98M | 24.32M | 26.99M |
| COGS % of Revenue | 72.26% | 27.17% | 19.92% | 17.29% | 42.63% | 41.13% | 35.09% | 45.54% | 51.18% |
| Gross Profit | 5.85M▲ 0% | 24.94M▲ 326.5% | 43.8M▲ 75.6% | 52.02M▲ 18.8% | 22M▼ 57.7% | 28.05M▲ 27.5% | 42.51M▲ 51.6% | 29.08M▼ 31.6% | 25.75M▼ 11.4% |
| Gross Margin % | 27.74% | 72.83% | 80.08% | 82.71% | 57.37% | 58.87% | 64.91% | 54.46% | 48.82% |
| Gross Profit Growth % | 629.96% | 326.51% | 75.63% | 18.78% | -57.71% | 27.48% | 51.58% | -31.6% | -11.45% |
| Operating Expenses | 40.36M | 44.25M | 54.52M | 49.31M | 42.46M | 41.06M | 32.05M | 25.16M | 31.25M |
| OpEx % of Revenue | 191.5% | 129.22% | 99.67% | 78.4% | 110.72% | 86.19% | 48.94% | 47.12% | 59.25% |
| Selling, General & Admin | 11.53M | 10.92M | 9.9M | 11.15M | 12.73M | 11.71M | 14.96M | 12.19M | 11.68M |
| SG&A % of Revenue | 54.7% | 31.88% | 18.1% | 17.72% | 33.19% | 24.58% | 22.84% | 22.83% | 22.15% |
| Research & Development | 28.83M | 33.33M | 44.62M | 38.17M | 29.73M | 29.35M | 17.09M | 12.97M | 19.57M |
| R&D % of Revenue | 136.8% | 97.34% | 81.58% | 60.68% | 77.53% | 61.61% | 26.1% | 24.29% | 37.1% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -34.52M▲ 0% | -19.31M▲ 44.1% | -10.72M▲ 44.5% | 2.71M▲ 125.3% | -20.46M▼ 855.1% | -13.01M▲ 36.4% | 10.46M▲ 180.4% | 3.92M▼ 62.6% | -5.5M▼ 240.4% |
| Operating Margin % | -163.76% | -56.39% | -19.59% | 4.31% | -53.36% | -27.32% | 15.97% | 7.34% | -10.43% |
| Operating Income Growth % | -4.08% | 44.06% | 44.49% | 125.29% | -855.06% | 36.4% | 180.38% | -62.55% | -240.41% |
| EBITDA | -32.6M | -17.64M | -9.1M | 4.01M | -19.34M | -11.93M | 11.65M | 5.22M | -4.04M |
| EBITDA Margin % | -154.65% | -51.51% | -16.64% | 6.38% | -50.44% | -25.04% | 17.79% | 9.78% | -7.65% |
| EBITDA Growth % | -4.54% | 45.89% | 48.4% | 144.09% | -582.15% | 38.34% | 197.68% | -55.19% | -177.28% |
| D&A (Non-Cash Add-back) | 1.92M | 1.67M | 1.62M | 1.3M | 1.12M | 1.09M | 1.19M | 1.3M | 1.47M |
| EBIT | -73.72M | -18.77M | -10.31M | 3.15M | -20.06M | -11.87M | 11.75M | 5.22M | -5.5M |
| Net Interest Income | -9.54M | -7.15M | -7.56M | -9.23M | -7.12M | -1.38M | -1.89M | 237K | -108K |
| Interest Income | 188K | 536K | 407K | 438K | 401K | 1.15M | 1.29M | 1.3M | 1.08M |
| Interest Expense | 9.72M | 7.68M | 7.97M | 9.67M | 7.52M | 2.53M | 3.18M | 1.06M | 1.19M |
| Other Income/Expense | -48.92M | -7.15M | -7.56M | -9.23M | -7.12M | -1.38M | -1.89M | 237K | -108K |
| Pretax Income | -83.44M▲ 0% | -26.46M▲ 68.3% | -18.28M▲ 30.9% | -6.52M▲ 64.3% | -27.58M▼ 322.8% | -14.4M▲ 47.8% | 8.57M▲ 159.5% | 4.15M▼ 51.5% | -5.61M▼ 235.0% |
| Pretax Margin % | -395.86% | -77.27% | -33.42% | -10.37% | -71.92% | -30.22% | 13.08% | 7.78% | -10.63% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 530K | 254K | 1.22M | 996K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | -3.68% | 2.97% | 29.42% | -17.76% |
| Net Income | -83.44M▲ 0% | -26.46M▲ 68.3% | -18.28M▲ 30.9% | -6.52M▲ 64.3% | -27.58M▼ 322.8% | -14.93M▲ 45.9% | 8.31M▲ 155.7% | 2.93M▼ 64.7% | -6.6M▼ 325.2% |
| Net Margin % | -395.86% | -77.27% | -33.42% | -10.37% | -71.92% | -31.33% | 12.69% | 5.49% | -12.52% |
| Net Income Growth % | -184.15% | 68.29% | 30.92% | 64.31% | -322.84% | 45.88% | 155.68% | -64.73% | -325.24% |
| Net Income (Continuing) | -83.44M | -26.46M | -18.28M | -6.52M | -27.58M | -14.93M | 8.31M | 2.93M | -6.6M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -6.50▲ 0% | -1.80▲ 72.3% | -1.23▲ 31.7% | -0.22▲ 82.1% | -0.62▼ 181.8% | -0.31▲ 50.0% | 0.10▲ 132.3% | 0.04▼ 63.4% | -0.08▼ 329.8% |
| EPS Growth % | -2141.38% | 72.31% | 31.67% | 82.11% | -181.82% | 50% | 132.26% | -63.4% | -329.78% |
| EPS (Basic) | -6.50 | -1.80 | -1.23 | -0.22 | -0.62 | -0.31 | 0.12 | 0.04 | -0.08 |
| Diluted Shares Outstanding | 13.11M | 14.71M | 14.84M | 29.15M | 44.14M | 48.47M | 82.42M | 81.06M | 78.55M |
| Basic Shares Outstanding | 13.11M | 14.71M | 14.84M | 29.15M | 44.14M | 48.47M | 67.51M | 72.53M | 78.55M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PLX Balance Sheet
Protalix BioTherapeutics, Inc. (PLX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 62.65M | 52.98M | 32.48M | 55.72M | 61.67M | 44.88M | 69.93M | 60.08M | 66.67M |
| Cash & Short-Term Investments | 51.16M | 37.81M | 17.79M | 38.55M | 38.98M | 22.18M | 44.56M | 34.83M | 14.68M |
| Cash Only | 51.16M | 37.81M | 17.79M | 18.27M | 38.98M | 17.11M | 23.63M | 19.76M | 14.68M |
| Short-Term Investments | 0 | 0 | 0 | 20.28M | 0 | 5.07M | 20.93M | 15.07M | 15.59M |
| Accounts Receivable | 1.72M | 4.73M | 4.7M | 2M | 3.44M | 4.59M | 5.27M | 2.91M | 8.84M |
| Days Sales Outstanding | 29.8 | 50.41 | 31.37 | 11.61 | 32.76 | 35.14 | 29.38 | 19.88 | 61.17 |
| Inventory | 7.83M | 8.57M | 8.15M | 13.08M | 17.95M | 16.8M | 19.05M | 21.24M | 25.73M |
| Days Inventory Outstanding | 187.71 | 336.24 | 273.21 | 439.15 | 400.83 | 313.06 | 302.47 | 318.83 | 347.91 |
| Other Current Assets | 1.5M | 1.42M | 1.52M | 1.25M | 380K | 536K | 611K | 596K | 17.42M |
| Total Non-Current Assets | 9.56M | 8.15M | 12.91M | 12.21M | 12M | 10.91M | 14.5M | 13.34M | 15.67M |
| Property, Plant & Equipment | 7.68M | 6.39M | 10.95M | 10.41M | 9.92M | 9.64M | 10.88M | 10.02M | 12.58M |
| Fixed Asset Turnover | 2.75x | 5.36x | 4.99x | 6.04x | 3.87x | 4.94x | 6.02x | 5.33x | 4.19x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.89M | 1.76M | 1.96M | 1.8M | 2.08M | 1.27M | 528K | 462K | 578K |
| Total Assets | 72.21M▲ 0% | 61.13M▼ 15.3% | 45.39M▼ 25.7% | 67.93M▲ 49.7% | 73.67M▲ 8.4% | 55.79M▼ 24.3% | 84.43M▲ 51.4% | 73.42M▼ 13.0% | 82.35M▲ 12.2% |
| Asset Turnover | 0.29x | 0.56x | 1.20x | 0.93x | 0.52x | 0.85x | 0.78x | 0.73x | 0.64x |
| Asset Growth % | -12.2% | -15.35% | -25.75% | 49.66% | 8.44% | -24.27% | 51.35% | -13.05% | 12.16% |
| Total Current Liabilities | 22.75M | 25.35M | 40.17M | 86.47M | 33.18M | 32.43M | 45.53M | 25.62M | 26.52M |
| Accounts Payable | 7.52M | 5.21M | 6.5M | 7.22M | 6.99M | 5.86M | 4.32M | 4.53M | 5.26M |
| Days Payables Outstanding | 180.24 | 204.47 | 217.59 | 242.4 | 155.97 | 109.21 | 68.61 | 68.04 | 71.11 |
| Short-Term Debt | 5.92M | 0 | 4.3M | 58.51M | 0 | 0 | 21.66M | 0 | 1.38M |
| Deferred Revenue (Current) | 26.85M | 9.87M | 16.34M | 5.39M | 8.55M | 13.18M | 0 | 0 | 0 |
| Other Current Liabilities | 526K | 9.18M | 1.75M | 1.53M | 1.51M | 11.05M | 4.94M | 1.81M | 16.93M |
| Current Ratio | 2.75x | 2.09x | 0.81x | 0.64x | 1.86x | 1.38x | 1.54x | 2.34x | 2.51x |
| Quick Ratio | 2.41x | 1.75x | 0.61x | 0.49x | 1.32x | 0.87x | 1.12x | 1.52x | 1.54x |
| Cash Conversion Cycle | 37.28 | 182.18 | 86.98 | 208.36 | 277.63 | 238.99 | 263.24 | 270.68 | 337.97 |
| Total Non-Current Liabilities | 80.75M | 88.66M | 75.54M | 8.5M | 46.52M | 34M | 5.33M | 4.58M | 7.6M |
| Long-Term Debt | 46.27M | 47.97M | 50.96M | 0 | 27.89M | 28.19M | 0 | 0 | 6.94M |
| Capital Lease Obligations | 0 | 0 | 4.53M | 4.47M | 4.38M | 4.17M | 4.62M | 4.03M | 6.94M |
| Deferred Tax Liabilities | 2.59M | 2.37M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 7.64M | 7.67M | 3.07M | 2.31M | 2.47M | 1.64M | 714K | 559K | 661K |
| Total Liabilities | 103.51M | 114.01M | 115.71M | 94.97M | 79.7M | 66.43M | 50.87M | 30.21M | 34.12M |
| Total Debt | 52.19M | 47.97M | 60.92M | 64.4M | 33.47M | 33.47M | 27.69M | 5.53M | 8.32M |
| Net Debt | 1.02M | 10.16M | 43.13M | 46.13M | -5.51M | 16.36M | 4.06M | -14.23M | -6.36M |
| Debt / Equity | - | - | - | - | - | - | 0.82x | 0.13x | 0.17x |
| Debt / EBITDA | - | - | - | 16.05x | - | - | 2.38x | 1.06x | - |
| Net Debt / EBITDA | - | - | - | 11.50x | - | - | 0.35x | -2.73x | - |
| Interest Coverage | -3.55x | -2.51x | -1.35x | 0.28x | -2.72x | -5.15x | 3.29x | 3.69x | -4.62x |
| Total Equity | -31.29M▲ 0% | -52.88M▼ 69.0% | -70.32M▼ 33.0% | -27.04M▲ 61.6% | -6.04M▲ 77.7% | -10.64M▼ 76.3% | 33.57M▲ 415.5% | 43.21M▲ 28.7% | 48.23M▲ 11.6% |
| Equity Growth % | -214.28% | -68.99% | -32.98% | 61.55% | 77.68% | -76.28% | 415.5% | 28.72% | 11.62% |
| Book Value per Share | -2.39 | -3.59 | -4.74 | -0.93 | -0.14 | -0.22 | 0.41 | 0.53 | 0.61 |
| Total Shareholders' Equity | -31.29M | -52.88M | -70.32M | -27.04M | -6.04M | -10.64M | 33.57M | 43.21M | 48.23M |
| Common Stock | 144K | 148K | 15K | 35K | 46K | 54K | 73K | 76K | 80K |
| Retained Earnings | -297.93M | -322.55M | -340.83M | -347.35M | -374.93M | -389.86M | -381.55M | -378.39M | -385M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -27.46M | -29.12M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PLX Cash Flow Statement
Protalix BioTherapeutics, Inc. (PLX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.99M | -7.74M | -19.36M | -26.11M | -10.29M | -25M | -1.32M | 8.67M | -11.99M |
| Operating CF Margin % | -47.41% | -22.61% | -35.39% | -41.51% | -26.82% | -52.48% | -2.01% | 16.24% | -22.74% |
| Operating CF Growth % | 68.86% | 22.53% | -150.04% | -34.86% | 60.6% | -143.07% | 94.73% | 758.12% | -238.26% |
| Net Income | -85.28M | -26.46M | -18.28M | -6.52M | -27.58M | -14.93M | 8.31M | 2.93M | -6.6M |
| Depreciation & Amortization | 1.92M | 1.67M | 1.62M | 1.3M | 1.12M | 1.09M | 1.19M | 1.3M | 0 |
| Stock-Based Compensation | 337K | 514K | 835K | 3.13M | 2.38M | 2.08M | 3.45M | 3.25M | 0 |
| Deferred Taxes | 39.35M | -64K | -68K | 0 | 0 | 0 | -3.09M | 236K | 0 |
| Other Non-Cash Items | 4.57M | 3.07M | 3.37M | 3.12M | 3.9M | -1.23M | -638K | 138K | 4.71M |
| Working Capital Changes | 29.1M | 13.53M | -6.83M | -27.13M | 9.9M | -12.02M | -10.54M | 811K | -10.1M |
| Change in Receivables | 25K | -3.1M | 188K | 2.09M | -1.03M | -1.19M | -428K | 2.32M | 0 |
| Change in Inventory | -2.59M | -736K | 414K | -4.93M | -4.87M | 1.15M | -2.24M | -2.2M | -4.49M |
| Change in Payables | 4.9M | -520K | 2.14M | 0 | 0 | 0 | 0 | 0 | 292K |
| Cash from Investing | -1.12M | -591K | -883K | -19.95M | 18.92M | -5.04M | -16.71M | 4.22M | -2.37M |
| Capital Expenditures | -971K | -686K | -627K | -655K | -1.46M | -628K | -1.15M | -1.28M | 0 |
| CapEx % of Revenue | 4.61% | 2% | 1.15% | 1.04% | 3.8% | 1.32% | 1.75% | 2.4% | 3.11% |
| Acquisitions | 3K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -148K | 95K | -256K | 703K | 380K | 593K | -142K | 83K | -2.37M |
| Cash from Financing | -1.42M | -4.75M | 0 | 46.47M | 12.08M | 8.24M | 24.67M | -16.79M | 9.33M |
| Debt Issued (Net) | -1.42M | -4.75M | 0 | -215K | -34.12M | 0 | 0 | -20.42M | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 472K | 0 | 2K | 712K | 0 | 0 |
| Net Change in Cash | -12.12M▲ 0% | -13.36M▼ 10.2% | -20.02M▼ 49.9% | 473K▲ 102.4% | 20.72M▲ 4280.5% | -21.87M▼ 205.6% | 6.52M▲ 129.8% | -3.87M▼ 159.4% | -4.38M▼ 13.0% |
| Free Cash Flow | -10.96M▲ 0% | -8.43M▲ 23.1% | -19.98M▼ 137.1% | -26.76M▼ 33.9% | -11.74M▲ 56.1% | -25.63M▼ 118.2% | -2.47M▲ 90.4% | 7.39M▲ 399.6% | -11.99M▼ 262.2% |
| FCF Margin % | -52.02% | -24.61% | -36.54% | -42.55% | -30.62% | -53.8% | -3.77% | 13.84% | -22.74% |
| FCF Growth % | 66.72% | 23.14% | -137.13% | -33.91% | 56.12% | -118.22% | 90.37% | 399.64% | -262.24% |
| FCF per Share | -0.84 | -0.57 | -1.35 | -0.92 | -0.27 | -0.53 | -0.03 | 0.09 | -0.15 |
| FCF Conversion (FCF/Net Income) | 0.12x | 0.29x | 1.06x | 4.00x | 0.37x | 1.67x | -0.16x | 2.96x | 1.82x |
| Interest Paid | 0 | 0 | 0 | 4.34M | 3.41M | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PLX Key Ratios
Protalix BioTherapeutics, Inc. (PLX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -6411.57% | - | - | - | - | - | - | 72.5% | 7.64% | -14.44% |
| Return on Invested Capital (ROIC) | -457.46% | - | - | - | - | -406.69% | -170.55% | 36.2% | 8.82% | -11.64% |
| Gross Margin | 8.71% | 27.74% | 72.83% | 80.08% | 82.71% | 57.37% | 58.87% | 64.91% | 54.46% | 48.82% |
| Net Margin | -319.22% | -395.86% | -77.27% | -33.42% | -10.37% | -71.92% | -31.33% | 12.69% | 5.49% | -12.52% |
| Debt / Equity | - | - | - | - | - | - | - | 0.82x | 0.13x | 0.17x |
| Interest Coverage | -7.91x | -3.55x | -2.51x | -1.35x | 0.28x | -2.72x | -5.15x | 3.29x | 3.69x | -4.62x |
| FCF Conversion | 1.09x | 0.12x | 0.29x | 1.06x | 4.00x | 0.37x | 1.67x | -0.16x | 2.96x | 1.82x |
| Revenue Growth | 110.79% | 129.13% | 62.44% | 59.73% | 15% | -39.03% | 24.22% | 37.48% | -18.47% | -1.23% |
PLX SEC Filings & Documents
Protalix BioTherapeutics, Inc. (PLX) SEC filings — annual & quarterly reports (10-K, 10-Q)
PLX Frequently Asked Questions
Protalix BioTherapeutics, Inc. (PLX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Protalix BioTherapeutics, Inc. (PLX) reported $52.7M in revenue for fiscal year 2025.
Protalix BioTherapeutics, Inc. (PLX) saw revenue decline by 1.2% over the past year.
Protalix BioTherapeutics, Inc. (PLX) reported a net loss of $6.6M for fiscal year 2025.
Dividend & Returns
Protalix BioTherapeutics, Inc. (PLX) has a return on equity (ROE) of -14.4%. Negative ROE indicates the company is unprofitable.
Protalix BioTherapeutics, Inc. (PLX) had negative free cash flow of $12.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More PLX
Protalix BioTherapeutics, Inc. (PLX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates